Dixon Terry C, Cunningham Coleen K
Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
Curr HIV/AIDS Rep. 2007 May;4(2):93-9. doi: 10.1007/s11904-007-0014-9.
The treatment of pediatric HIV infection has seen vast improvements in terms of better long-term suppression of HIV replication and subsequent improvements in the longevity and quality of life in children. This has been realized, in part, by development of newer antiretroviral medications, better knowledge about the pharmaco-kinetics of these drugs in children, and improved insight on drug toxicities in children. This review will discuss some of the newer agents that may be available for children in the near future, in addition to new pharmacokinetic and toxicity data that are specific to the pediatric patient. New information on key vaccines that should be administered to children with HIV infection is also discussed.
在长期更好地抑制HIV复制以及随后改善儿童寿命和生活质量方面，儿科HIV感染的治疗取得了巨大进展。这在一定程度上得益于新型抗逆转录病毒药物的研发、对这些药物在儿童体内药代动力学的更深入了解以及对儿童药物毒性的更深入认识。本综述将讨论一些在不久的将来可能可供儿童使用的新型药物，以及儿科患者特有的新的药代动力学和毒性数据。还将讨论关于应接种给HIV感染儿童的关键疫苗的新信息。
